Studies utilising serial CK18 measurements to determine tumour responses to cytotoxic therapy in pancreatic cancer should give adequate consideration to the potential confounding factors of concurrent obstructive jaundice and the duration of sample storage. This evidence concerns the gene KRT18 and pancreatic neoplasm.